Neurodegenerative diseases are driven by complex biological processes that unfold over years, spanning neuronal dysfunction, neuroinflammation, metabolic dysregulation, and systemic contributions outside the central nervous system. While genetics and imaging provide important context, they often fail to explain why patients with similar risk profiles experience markedly different disease trajectories and therapeutic responses.
Sapient’s approaches to identifying biomarkers and targets for CNS disease directly measure the dynamic molecular layers that read out neurodegeneration via protein, metabolite, lipid, and cytokine profiling – including non-invasive capture of CNS‑derived biology from blood.
How do CNS‑originating signals differ among patients with similar genetics or imaging findings?
How does peripheral inflammation and metabolism interface with CNS disease pathology?
Which targets actively modulate disease processes rather than statically predict risk?
Which molecular pathways driving neurodegeneration are detectable in blood for non-invasive monitoring?
Dechiper functional differences among patients who appear similar based on genetics, imaging, or clinical presentation, revealing distinct disease mechanisms that inform more precise target selection.
Leverage non-invasive sampling to longitudinally evaluate biomarkers and therapies by tracking pathway engagement, neuroinflammatory signaling, and metabolic changes with treatment exposure.
Ground CNS targets and markers in human-relevant evidence by validating their associations with disease state and progression across independent cohorts in DynamiQ before advancing programs.
We leverage our innovative mass spectrometry-based platforms alongside ultra-sensitive NULISA assays to capture the breadth of CNS disease biology. These include:
See how Sapient not only on generates robust proteomics data from CSF samples, but also leverages it for key actionable insight – annotating hundreds of key pathways and processes to map proteins across core signaling pathways and cascades involved in neurodegeneration.
DynamiQ is Sapient’s longitudinal molecular‑clinical data resource, built from tens of thousands of deeply phenotyped human samples. Once biomarkers or targets are identified in your study, DynamiQ enables:
Bridge the gap between inferred and functional biology to de-risk translation.
Layer your data and ours to orthogonally validate findings and extend discoveries.
Resolve distinct mechanisms within shared diagnoses to subgroup patient populations.
Connect with our scientists to discuss your neurodegeneration programs. Sapient can help you identify biomarkers and targets for CNS disease that are biologically grounded and positioned to translate – using blood‑based molecular insights to illuminate the biology of the brain.
